Wall Street brokerages expect that Nabriva Therapeutics PLC – (NASDAQ:NBRV) will post ($0.35) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Nabriva Therapeutics’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.36). Nabriva Therapeutics posted earnings of ($0.60) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 41.7%. The firm is expected to issue its next earnings results on Friday, March 15th.
On average, analysts expect that Nabriva Therapeutics will report full year earnings of ($2.12) per share for the current financial year, with EPS estimates ranging from ($2.20) to ($2.05). For the next financial year, analysts expect that the business will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.46) to ($1.14). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Nabriva Therapeutics.
Several equities research analysts have recently commented on NBRV shares. Zacks Investment Research raised shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Wednesday, January 2nd. BidaskClub downgraded shares of Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 15th. SunTrust Banks decreased their target price on shares of Nabriva Therapeutics to $11.00 and set a “buy” rating for the company in a research report on Wednesday, November 14th. ValuEngine raised shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Nabriva Therapeutics in a research report on Monday, January 28th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $9.89.
In other Nabriva Therapeutics news, Director Charles A. Rowland, Jr. bought 53,000 shares of the firm’s stock in a transaction dated Monday, December 24th. The stock was bought at an average cost of $1.31 per share, with a total value of $69,430.00. Following the completion of the transaction, the director now directly owns 53,000 shares in the company, valued at approximately $69,430. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.15% of the company’s stock.
Several large investors have recently bought and sold shares of NBRV. Wedbush Securities Inc. boosted its holdings in Nabriva Therapeutics by 12.5% during the fourth quarter. Wedbush Securities Inc. now owns 103,550 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 11,500 shares during the last quarter. Bank of America Corp DE boosted its holdings in Nabriva Therapeutics by 4,353.6% during the second quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 54,159 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Nabriva Therapeutics during the third quarter worth about $431,000. Clear Harbor Asset Management LLC boosted its holdings in Nabriva Therapeutics by 1,195.7% during the third quarter. Clear Harbor Asset Management LLC now owns 212,500 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 196,100 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Nabriva Therapeutics by 2,128.9% during the third quarter. Renaissance Technologies LLC now owns 285,300 shares of the biotechnology company’s stock worth $770,000 after purchasing an additional 272,500 shares during the last quarter. 4.76% of the stock is owned by institutional investors.
NBRV traded down $0.04 during midday trading on Monday, hitting $2.02. The company had a trading volume of 291,300 shares, compared to its average volume of 548,764. Nabriva Therapeutics has a 52 week low of $1.12 and a 52 week high of $6.40. The company has a current ratio of 7.35, a quick ratio of 7.35 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.41 billion, a P/E ratio of -0.81 and a beta of 2.27.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Recommended Story: Understanding each part of a balance sheet
Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.